July 23, 2009, Updated September 24, 2012
Jul. 22 – Israel drug delivery systems developer Oramed Pharmaceuticals, has reported positive results from a Phase 2A study of its oral insulin capsule, ORMD-0801, on type 1 diabetic patients.
The completion of this study marks Oramed’s first clinical trial on patients with type 1 diabetes Mellitus. In the trial, Oramed’s oral capsule, was well tolerated by patients and no serious adverse events were observed.
The insulin absorption was not affected when given before meal ingestion. Jerusalem-based Oramed, which was founded in 2006, is now conducting a Phase 2B clinical trial in South Africa, on type 2 diabetic patients. The company’s technology is based on over 25 years of research by scientists at Jerusalem’s Hadassah Medical Center.
For Email Marketing you can trust
Fighting for Israel's truth
We cover what makes life in Israel so special — it's people. A non-profit organization, ISRAEL21c's team of journalists are committed to telling stories that humanize Israelis and show their positive impact on our world. You can bring these stories to life by making a donation of $6/month.
